Expression of IL-17A concentration and effector functions of peripheral blood neutrophils in food allergy hypersensitivity patients

Żbikowska-Gotz, Magdalena; Pałgan, Krzysztof; Gawrońska-Ukleja, Ewa; Kuźmiński, Andrzej; Przybyszewski, Michał; Socha, Ewa; Bartuzi, Zbigniew

doi:10.1177/0394632015617069

Cited by 23 publications

(17 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study has shown that neutrophils are activated in the early stage of acute human anaphylaxis [16]. Previous studies conducted by the authors of this study confirmed that neutrophils are rapidly activated during allergic food hypersensitivity and are important elements of non-specific immune response [17]. These studies suggest a potential VIT [20,21].…”

Section: Discussionsupporting

confidence: 73%

The effect of hymenoptera venom immunotherapy on neutrophils, interleukin 8 (IL-8) and interleukin 17 (IL-17)

Pałgan¹,

Żbikowska-Gotz²,

Zacniewski³

et al. 2020

Int J Occup Med Environ Health

Self Cite

View full text Add to dashboard Cite

Objectives: Venom immunotherapy (VIT) is an effective treatment method and is addressed to patients with a history of an anaphylactic reaction to Hymenoptera stings. However, the immunological mechanisms of protection have not been explained yet. The objective of this study was to analyze neutrophils, interleukin 8 (IL-8) and interleukin 17 (IL-17) before and after the initial phase of the immunotherapy. Material and Methods: Overall, 40 individuals, including 20 wasp venom sensitized and 20 bee venom sensitized patients, were included in the study. The patients had had a history of severe allergic reactions type III and IV according to Mueller's classification. An ultra-rush VIT protocol was used in this study. The concentration of serum IL-8 and IL-17A was determined using the ELISA enzymatic method. Results: The authors demonstrated a significant rise in the IL-8 level after the immunotherapy, compared to baseline (14.9 vs. 24.7, p < 0.05). The rise in the neutrophils level was also noticeable but proved to be barely out of the range of statistical significance (4.3 vs. 5.0, p = 0.06). The shift in IL-17A was negligent and not statistically significant in the paired samples t-test (1.6 vs. 1.5, p = 0.34). Conclusions: Venom immunotherapy induces neutrophils and IL-8 activity after 2 days. After the desensitization, the level of IL-17A did not change.

show abstract

Section: Discussionsupporting

confidence: 73%

The effect of hymenoptera venom immunotherapy on neutrophils, interleukin 8 (IL-8) and interleukin 17 (IL-17)

Pałgan¹,

Żbikowska-Gotz²,

Zacniewski³

et al. 2020

Int J Occup Med Environ Health

Self Cite

View full text Add to dashboard Cite

show abstract

“…Most of the cytokines levels on day 90 in this patient were ≤2-fold different from the average levels of all course 4 AR patients. One exception was IL-17A, a cytokine known to be associated with food allergy ( 16 ). The IL-17A levels in this patient (4.02 ± 0.14) were higher than 29 of 32 (91%) patients who did not have any AR.…”

Section: Resultsmentioning

confidence: 99%

A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931

et al. 2018

View full text Add to dashboard Cite

PurposeA phase 3 randomized study (COG ANBL0032) demonstrated significantly improved outcome by adding immunotherapy with ch14.18 antibody to isotretinoin as post-consolidation therapy for high-risk neuroblastoma (NB). This study, ANBL0931, was designed to collect FDA-required safety/toxicity data to support FDA registration of ch14.18.Experimental designNewly diagnosed high-risk NB patients who achieved at least a partial response to induction therapy and received myeloablative consolidation with stem cell rescue were enrolled to receive six courses of isotretinoin with five concomitant cycles of ch14.18 combined with GM-CSF or IL2. Ch14.18 infusion time was 10–20 h per dose. Blood was collected for cytokine analysis and its association with toxicities and outcome.ResultsOf 105 patients enrolled, five patients developed protocol-defined unacceptable toxicities. The most common grade ≥ 3 non-hematologic toxicities of immunotherapy for cycles 1–5, respectively, were neuropathic pain (41, 28, 22, 31, 24%), hypotension (10, 17, 4, 14, 8%), allergic reactions (ARs) (3, 10, 5, 7, 2%), capillary leak syndrome (1, 4, 0, 2, 0%), and fever (21, 59, 6, 32, 5%). The 3-year event-free survival and overall survival were 67.6 ± 4.8% and 79.1 ± 4.2%, respectively. AR during course 1 was associated with elevated serum levels of IL-1Ra and IFNγ, while severe hypotension during this course was associated with low IL5 and nitrate. Higher pretreatment CXCL9 level was associated with poorer event-free survival (EFS).ConclusionThis study has confirmed the significant, but manageable treatment-related toxicities of this immunotherapy and identified possible cytokine biomarkers associated with select toxicities and outcome. EFS and OS appear similar to that previously reported on ANBL0032.

show abstract

“…This interleukin family consists of IL-17, IL-17B, IL-17C, IL-17D, IL-17E (also called IL-25) and IL-17F. IL-17E/ IL-25 is produced by mast cells, Th2 cells, eosinophils, basophils, alveolar macrophages, microglia, epithelial and endothelial cells [33,34]. There are many studies indicating that IL-17E/IL-25 plays an important role in the pathogenesis of allergic diseases [35,36].…”

Section: Discussionmentioning

confidence: 99%

Expression of eosinophils, RANTES and IL-25 in the first phase of Hymenoptera venom immunotherapy

Pałgan

Żbikowska-Gotz

Bartuzi

2020

pdia

Self Cite

View full text Add to dashboard Cite

Introduction: Venom immunotherapy (VIT) can protect against severe anaphylactic reactions (SR) in 80-100% of subjects allergic to Hymenoptera venom. The mechanisms of induction of immunological tolerance produced by VIT are still little known. It has been shown that VIT modulates Treg activity, Th2 or Th1 cells or both, increases production of IL-10, decreases secretion of IL-13, and causes an IgG4/IgE ratio shift. Aim: To investigate the blood eosinophil count, CCL5/RANTES and IL-17E/IL-25 concentrations before and after the initial phases of the rush protocol of VIT. Material and methods: Forty individuals (14 males, 26 females) of mean age 41.03 ±12.43 years were included in the study. The peripheral eosinophils and the concentration of serum interleukin IL-17E/IL-25 and RANTES were determined before and after the initial phase of VIT. Results: Paired sample t-test revealed that all patients after VIT had significantly higher eosinophil levels compared to the baseline (mean: 0.42 vs. 0.64, p < 0.05). Moreover, in subjects treated with bee venom, RANTES levels proved to rise significantly (51 × 10 3 vs. 62 × 10 3 , p < 0.05) while IL-17E/IL-25 dropped with near-marginal significance (916 vs. 650, p = 0.069). Conclusions: Our immunological study on the early phase of venom immunotherapy suggested that eosinophils, cytokines such as CCL5/RANTES and IL-17E/IL-25 contribute to the immunological response.

show abstract

Expression of IL-17A concentration and effector functions of peripheral blood neutrophils in food allergy hypersensitivity patients

Cited by 23 publications

References 35 publications

The effect of hymenoptera venom immunotherapy on neutrophils, interleukin 8 (IL-8) and interleukin 17 (IL-17)

The effect of hymenoptera venom immunotherapy on neutrophils, interleukin 8 (IL-8) and interleukin 17 (IL-17)

A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931

Expression of eosinophils, RANTES and IL-25 in the first phase of Hymenoptera venom immunotherapy

Contact Info

Product

Resources

About